Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses

BACKGROUND: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy are a mainstay treatment for hormone receptor-positive breast cancer. While their principal mechanism is inhibition of cancer cell proliferation, preclinical and clinical evidence suggests that CDK4/6i can a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Amrendra, Ramani, Vijay, Bharti, Vijaya, de Lima Bellan, Daniel, Saleh, Nabil, Uzhachenko, Roman, Shen, Chengli, Arteaga, Carlos, Richmond, Ann, Reddy, Sangeetha M, Vilgelm, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231009/
https://www.ncbi.nlm.nih.gov/pubmed/37230537
http://dx.doi.org/10.1136/jitc-2022-006019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231009/
https://www.ncbi.nlm.nih.gov/pubmed/37230537
http://dx.doi.org/10.1136/jitc-2022-006019

Ejemplares similares